Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24752718 | 0.74 | CYP3A4 (0.33) | KDM4EALDH1A1LMNACYP3A4HPGD | |
| SCHEMBL17774720 | 0.74 | IDO1 (0.45) | KDM4EALDH1A1CYP3A4HPGDSMN1; SMN2 | |
| SCHEMBL31417703 | 0.74 | HTR2A (0.32) | — | |
| SCHEMBL31364787 | 0.74 | NR4A2 (0.35) | ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL7064960 | 0.74 | IDO1 (0.50) | KDM4EALDH1A1LMNACYP3A4HPGD | |
| SCHEMBL22595265 | 0.69 | KCNA2 (0.34) | KDM4EALDH1A1LMNACYP3A4HPGD | |
| SCHEMBL13255241 | 0.69 | HSP90AB1 (0.35) | — | |
| SCHEMBL25033145 | 0.69 | — | — | |
| SCHEMBL658316 | 0.69 | IDO1 (0.33) | — | |
| SCHEMBL4416706 | 0.69 | HTR2A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2022253081-A1 | PHOSPHINE OXIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 希格生科（深圳）有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB | 2007-08-16 | — | — | US | disclosed |
| US-7173136-B2 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20050282856-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| EP-1575943-A1 | 3-CYANO-QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004041811-A1 | 3-CYANO-QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282856-A1 | 3-Cyano-quinoline derivatives | MKI67, CCNA1, CCNT1 | KDM4E 1779/4885ALDH1A1 1113/4885LMNA 422/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | KDM4E 3421/4885ALDH1A1 4648/4885LMNA 212/4885 |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | MKI67, CCNA1, CCNT1 | KDM4E 1779/4885ALDH1A1 1113/4885LMNA 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.